Shire's experimental drug to treat attention-deficit hyperactive disorder showed positive results in a recent study, bringing the company one step closer to earning approval from the Food and Drug Administration.
SHP465 isan investigational oral stimulant medication intended to treat adults with ADHD.Two different doses of the drug treated 275 patients with ADHD more effectively than a placebo, according to a recent study led by Matthew Brams, MD, Clinical Assistant Professor at Baylor College of Medicine in Houston
Dublin-based Shire already sells Vynase and Intunic for treatment of the condition, with its ADHD drug franchise patent-protected until 2029.
"ADHD affects adults in multiple ways and, therefore, physicians need additional treatment options. Based upon this study's findings, and pending the U.S. FDA's review, SHP465 may provide a promising treatment option for physicians and patients alike," said Matthew Brams, MD, lead investigator of the study.
Shire plans to submit a New Drug Application to the FDA by the end of the year and hopes to gain approval for SHP465 in late 2017.
More articles on the drug market:
FDA approves drug for treatment of 6 types of hepatitis C
Pfizer to build $350M biotech center in China
Roche's new MS drug to hit market sooner than expected